CR9's Principal Activity is
the exploration and development of their 100% owned Tampu, Wiltshire and Kalannie kaolin projects along with the 100% owned Bonnie Rock silica project which are all located in the mid-west of Western Australia.
Share Price Activity
Last (Price)
Change
0.00
(0.00)
Bid / Ask
-
Volume
Volume (4w avg)
Turnover
Open
Day Range
-
VWAP
Prev Close
Last Trade
Performance
1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr)
-
vs ASX 200 (1yr)
-19.51%
Size
Market Cap
Excludes mandatory escrowed shares and foreign shares.
Corella Resources Ltd (CR9, formerly Sinetech Limited) is an Australian exploration company listed on the Australian Stock Exchange (ASX:CR9). The Company's main focus is on the exploration of the following wholly owned, high-grade, low impurity kaolin and silica projects located in the Yilgarn Craton region of Western Australia: Tampu Kaolin Project, Wiltshire Kaolin Project, Kalannie Kaolin Project and Bonnie Rock Silica Project.
Incorporation Details
Incorporated Incorporated on 14 June 2007 in Western Australia.
Mr Cormack has over 25 years of experience as a geologist with expertise in exploration, project management and resource estimation working across numerous jurisdictions internationally, including Australia, Canada, USA and South Korea. Mr Cormack has held several senior roles including resource development manager with Atlas Iron, geology team leader at BHP's Area C project. Mr Cormack's most recent company North West Nickel sold to Chalice Mining Limited (ASX: CHN) in 2019.
Mr Philip Re
Non-Executive Director
Apr 2021
Mr Philip Re
Non-Executive Director
Mr Re specialises in corporate advisory, corporate governance, mergers and acquisitions and investment banking for ASX listed Companies.
Mr Peter Woods
Non-Executive Director
Apr 2021
Mr Peter Woods
Non-Executive Director
Mr Woods has over 14 years experience in the financial services industry specialising in wealth advisory, raising capital for both unlisted and listed companies, structuring, transactions and business development. He has corporate finance, capital markets and investment advisory experience across various industries and geographies. Mr Woods is founding director of Bluebird Capital, a project generation, investment and corporate advisory business. Mr Woods has recently completed an executive education course on Private Equity and Venture Capital at Harvard Business School, Boston USA.
Mr Daniel Coletta
Joint Company Secretary
Dec 2020
Mr Daniel Coletta
Joint Company Secretary
Mr Coletta has experience in accounting and compliance.
Mr Derek Hall
Company Secretary
Dec 2019
Mr Derek Hall
Company Secretary
Mr Hall is a finance and compliance specialist in the listed space. Mr Hall has commercial experience identifying key business drivers and bringing cost control and process improvement into sharp focus. Mr Hall has been involved as a Chief Financial Officer and Company Secretary for a number of publicly listed and unlisted companies involving transactions in technology, mining, oil and gas and construction.
Dr Paul Bello
Joint Company Secretary
Oct 2008
Mr Giorgio Reggiani
Company Secretary
Feb 2008
Mr Harry Karelis
Non-Executive Director
N/A
Mr Harry Karelis
Non-Executive Director
--
Mr Leslie Harold Webb
Non-Executive Director
N/A
Mr Leslie Harold Webb
Non-Executive Director
Mr Webb was establishing ITV Consulting Pty Limited, a corporate advisory and investment consulting business. He is also a Non-executive Director of pharmaceutical company Generic Health Limited and health insurance company iSelect. He previously sat on the Board of the ASX listed Gradipore Ltd (now Life Therapeutics).
Mr David Dodd
Chairman
N/A
Mr David Dodd
Chairman
Mr Dodd's experience includes management and corporate development experience in the life sciences industry. Prior to joining the Stem Cell Sciences, he was President, Chief Executive Officer and Director of NASDAQ quoted Serologicals Corporation until it was acquired by Millipore Corporation on 14 July 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board for the Pharmaceutical Sector for Solvay SA. He was also Chairman of the Board of Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. He was awarded the 2005 GBP Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. In addition, he received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the USA and the United Kingdom. David is also currently serving on the board of directors of Stheno Corporation, a private life sciences instrument company, as Non-executive Director; as Chairman of the Board of the American Foundation for Suicide Prevention; and, as Immediate Past-Chair, the Georgia Biomedical Partnership, and the biotechnology trade association in the State of Georgia. He was appointed President, CEO and Chairman of Bioreliance Corporation on 3 December 2007.
Dr Peter Mountford
Non-Executive Director
N/A
Dr Peter Mountford
Non-Executive Director
Dr Mountford is currently a Director of all the companies within Stem Cell Sciences, as well as of the private company Secure Sciences Pty Ltd.
Dr Michael (Mike) Dexter
Non-Executive Director
N/A
Dr Michael (Mike) Dexter
Non-Executive Director
Dr Dexter spent the five years prior to joining Stem Cell Sciences as Director (Chief Executive Officer) of The Wellcome Trust. During his time at The Wellcome Trust, he oversaw one of the biggest advances in biomedical research when it was announced that the human genome had been sequenced - giving scientists a detailed map of the body's make-up for the first time. Prior to joining The Wellcome Trust, he was Director of Research at the Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester. He is a Fellow of the Royal Society (London), was appointed Professor of Experimental Oncology at the University of Manchester and is an honorary Fellow of the Royal College of Physicians and a founding fellow of the Academy of Medical Sciences. He is currently Chairman of the International Centre for Life, Newcastle, and the Cockcroft Institute for Accelerator Sciences in Daresbury, Cheshire. He was previously a Director of Catalyst Biomedica Ltd, the translational business arm of The Wellcome Trust. He has over 360 publications on his scientific work.
Dr Alastair James Riddell
Chief Executive Officer
N/A
Dr Alastair James Riddell
Chief Executive Officer
Dr Riddell has more than 24 years experience in this industry. He has spent time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007, he held the position of Non-executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, he was Chief Executive Officer of Pharmagene for seven years, during which time he listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. He began his professional career as a medical doctor with six years, experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007, he joined the Board of Sareum Holdings plc as Non-executive Director.
Paul Bello
Joint Company Secretary
N/A
Director Transactions
CR9 directors must report any change in shareholding to the ASX within 5 business days.
Data supplied by Morningstar and accurate on Sep 9, 2021.
It's not possible to publish a real-time Top 20 Shareholder list.
Companies are not obliged to report this data (with the exception of Substantial
Shareholders above 5%). If a company chooses to publish the data,
it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report
being published and the data appearing on Market Index (<7 days for ASX 300
and up to 30 days for micro-caps).
Name
Shares
Capital
Celtic Capital Pty Ltd <The Celtic Capital A/C>
15,000,000
3.53%
Jindabyne Capital Pty Ltd
14,000,000
3.29%
Mr Anthony Stephen Cormack
13,909,091
3.27%
Mr Julian Rodney Stephens <One Way A/C>
12,909,091
3.04%
Hekima Pty Ltd <Ocean Trust A/C>
12,500,000
2.94%
Ms Katherine Gaye Macpherson
12,500,000
2.94%
Yuan By Yuan Capital Pty Ltd <Yo Yo Trading Trust A/C>
12,500,000
2.94%
Ionian Holdings Pty Ltd
10,000,000
2.35%
Blackbird Capital Pty Ltd <Blackbird A/C>
9,500,000
2.24%
Mr Samuel Radford Moyle <Sam Moyle Family Trust A/C>
8,060,606
1.90%
Mr Dylan Jensen <Blencowe Investment A/C>
8,060,606
1.90%
Mr Simon William Vincent <S Vincent Family A/C>
8,060,606
1.90%
Ligurian Holdings Pty Ltd
7,900,011
1.86%
High Conviction Holdings Pty Ltd <Smith Family A/C>
A substantial shareholder is a person or entity that owns 5% or more of
the voting shares in a company. Shares can be held through multiple
entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market.
When all “Last Notice” dates are identical, it suggests that no (or minimal)
change
has occurred since the most recent Annual Report.
Name
Last Notice
Total Shares
Shares Held (%)
Jason Peterson and associated entities
09/09/2021
22,000,000
5.20
Peter Woods and associated entities
09/09/2021
22,000,000
5.20
Shareholders Buying
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
Shareholders Selling
12 month transaction history compiled from ASX announcements.